Publications by authors named "Caroline Breitbach"

Claim this Profile
K
Kinetics of Nirogacestat-Mediated Increases in B-cell Maturation Antigen on Plasma Cells Inform Therapeutic Combinations in Multiple Myeloma.
Todd Shearer, Melissa Comstock, Rex L Williams, Mark C Johnson, Ewa Cendrowicz, Caroline J Breitbach

Cancer Res Commun· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PHOCUS: A Phase 3, Randomized, Open-Label Study of Sequential Treatment with Pexa-Vec (JX-594) and Sorafenib in Patients with Advanced Hepatocellular Carcinoma.
Ghassan K Abou-Alfa, Peter R Galle, Yee Chao, Joseph Erinjeri, Jeong Heo, Caroline Breitbach

Liver Cancer· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oncolytic virus driven T-cell-based combination immunotherapy platform for colorectal cancer.
Mathieu J F Crupi, Zaid Taha, Thijs J A Janssen, Julia Petryk, Stephen Boulton, Caroline J Breitbach

Front Immunol· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Considerations for Clinical Translation of MG1 Maraba Virus.
Caroline J Breitbach

Methods Mol Biol· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development and applications of oncolytic Maraba virus vaccines.
Jonathan G Pol, Matthew J Atherton, Byram W Bridle, Kyle B Stephenson, Fabrice Le Boeuf, Caroline J Breitbach

Oncolytic Virother· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical evaluation of a MAGE-A3 vaccination utilizing the oncolytic Maraba virus currently in first-in-human trials.
Jonathan G Pol, Sergio A Acuna, Beta Yadollahi, Nan Tang, Kyle B Stephenson, Caroline J Breitbach

Oncoimmunology· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Amplification of Oncolytic Vaccinia Virus Widespread Tumor Cell Killing by Sunitinib through Multiple Mechanisms.
Minah Kim, Maximilian Nitschké, Barbara Sennino, Patrizia Murer, Brian J Schriver, Caroline J Breitbach

Cancer Res· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The emerging therapeutic potential of the oncolytic immunotherapeutic Pexa-Vec (JX-594).
Caroline J Breitbach, John C Bell, Tae-Ho Hwang, David H Kirn, James Burke

Oncolytic Virother· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 Study of Intravenous Oncolytic Poxvirus (vvDD) in Patients With Advanced Solid Cancers.
Stephanie Downs-Canner, Zong Sheng Guo, Roshni Ravindranathan, Caroline J Breitbach, Mark E O'Malley

Mol Ther· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oncolytic Viruses: Therapeutics With an Identity Crisis.
Caroline J Breitbach, Brian D Lichty, John C Bell

EBioMedicine· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase 2, Open-Label, Randomized Study of Pexa-Vec (JX-594) Administered by Intratumoral Injection in Patients with Unresectable Primary Hepatocellular Carcinoma.
Caroline J Breitbach, Anne Moon, James Burke, Tae-Ho Hwang, David H Kirn

Methods Mol Biol· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1b Trial of Biweekly Intravenous Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus in Colorectal Cancer.
Se Hoon Park, Caroline J Breitbach, Jeeyun Lee, Joon Oh Park, Ho Yeong Lim

Mol Ther· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pexa-Vec double agent engineered vaccinia: oncolytic and active immunotherapeutic.
Caroline J Breitbach, Kelley Parato, James Burke, Tae-Ho Hwang, John C Bell

Curr Opin Virol· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oncolytic viruses: perspectives on clinical development.
James Burke, Jorge Nieva, Mitesh J Borad, Caroline J Breitbach

Curr Opin Virol· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
VEGF-Mediated Induction of PRD1-BF1/Blimp1 Expression Sensitizes Tumor Vasculature to Oncolytic Virus Infection.
Rozanne Arulanandam, Cory Batenchuk, Fernando A Angarita, Kathryn Ottolino-Perry, Sophie Cousineau, Caroline J Breitbach

Cancer Cell· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Complement inhibition prevents oncolytic vaccinia virus neutralization in immune humans and cynomolgus macaques.
Laura Evgin, Sergio A Acuna, Christiano Tanese de Souza, Monique Marguerie, Chantal G Lemay, Caroline J Breitbach

Mol Ther· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 study of intratumoral Pexa-Vec (JX-594), an oncolytic and immunotherapeutic vaccinia virus, in pediatric cancer patients.
Timothy P Cripe, Minhtran C Ngo, James I Geller, Chrystal U Louis, Mark A Currier, Caroline J Breitbach

Mol Ther· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-man study of western reserve strain oncolytic vaccinia virus: safety, systemic spread, and antitumor activity.
Herbert J Zeh, Stephanie Downs-Canner, J Andrea McCart, Zong Sheng Guo, Uma N M Rao, Caroline J Breitbach

Mol Ther· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Going viral with cancer immunotherapy.
Brian D Lichty, Caroline J Breitbach, David F Stojdl, John C Bell

Nat Rev Cancer· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oncolytic virotherapy as emerging immunotherapeutic modality: potential of parvovirus h-1.
Markus Moehler, Katrin Goepfert, Bernd Heinrich, Caroline J Breitbach, Maike Delic

Front Oncol· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oncolytic and immunotherapeutic vaccinia induces antibody-mediated complement-dependent cancer cell lysis in humans.
Mi Kyung Kim, Caroline J Breitbach, Anne Moon, Jeong Heo, Yu Kyoung Lee

Sci Transl Med· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer.
Jeong Heo, Tony Reid, Leyo Ruo, Caroline J Breitbach, Steven Rose

Nat Med· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oncolytic vaccinia virus disrupts tumor-associated vasculature in humans.
Caroline J Breitbach, Rozanne Arulanandam, Naomi De Silva, Steve H Thorne, Richard Patt

Cancer Res· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preventing postoperative metastatic disease by inhibiting surgery-induced dysfunction in natural killer cells.
Lee-Hwa Tai, Christiano Tanese de Souza, Simon Bélanger, Lundi Ly, Almohanad A Alkayyal, Caroline J Breitbach

Cancer Res· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers.
Kelley A Parato, Caroline J Breitbach, Fabrice Le Boeuf, Jiahu Wang, Chris Storbeck

Mol Ther· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis